Decoding Neoantigen-encoding Tumor-Specific Transcripts Unveils a Shared Target Reservoir for Immunotherapy in Hepatocellular Carcinoma
Peng LiniD, Yifan Wen, Jingjing ZhaoiD, Feifei Zhang, Yaoming Su, Hongwu Yu, Yu Hx, Qiaojuan Li, Chengye LiuiD, Zhixiang HuiD, Yan LiiD, Zhuting Fang, Linhui Liang, Shenglin HuangiD
Abstract
Background and AimsPrimary liver cancer, predominantly hepatocellular carcinoma (HCC), has limited therapeutic options. While mutation-derived neoantigen vaccine holds promise, its success is hindered by low antigen availability. This study explores transcriptome-derived neoantigens (neoantigen-encoding tumor-specific transcripts, neoTSTs) in HCC, characterizing their features, generation mechanisms, and therapeutic potential. Approach and ResultsWe analyzed RNA-seq data from 1,013 liver cancer patients and constructed a multi-layered reference dataset. Using a customized pipeline, we identified an average of 60 neoTSTs per patient, significantly surpassing mutation-derived neoantigens (neoMuts). NeoTSTs exhibited higher population frequencies, with 73.1% providing multiple epitopes, and were validated through mass spectrometry and HLA transgenic mouse models. Mechanistically, neoTSTs were generated via retained introns, transposable element activation, HNF4A-regulated alternative promoters, and de novo transmembrane domain (TMD) generation. Single-cell analysis revealed neoTSTs cover >75% of tumor cells and identified antigen-presenting cancer-associated fibroblasts (apCAFs) that enriched in immunotherapy responders and amplified CD4 T-cell responses via MHC-II presentation. In murine HCC models, neoTST vaccination outperformed neoMuts, inducing dual MHC-I/II activation and significant tumor growth inhibition. ConclusionsNeoTSTs represent a superior neoantigen source in HCC, compensating for the limitations of mutation-derived targets. Their abundance, sharedness, and dual MHC pathway activation highlight their potential for personalized immunotherapy, particularly in low-TMB tumors. Graphic Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=178 SRC="FIGDIR/small/692877v1_ufig1.gif" ALT="Figure 1"> View larger version (44K): org.highwire.dtl.DTLVardef@1bedfedorg.highwire.dtl.DTLVardef@5f6c95org.highwire.dtl.DTLVardef@d1deb5org.highwire.dtl.DTLVardef@743e85_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 0th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Non-canonical ORFs are an important source of tumor-specific antigens in a liver cancer meta-cohort
Marta E. Camarena, Patrick Theunissen, … M. Mar Albà·bioRxiv·Oct 30, 2023
- Harnessing Tumor-Specific Transcript Diversity Uncovers a Shared Neoantigen Reservoir for Pancreatic Ductal Adenocarcinoma
Jingjing Zhao, Qiaojuan Li, … Shenglin Huang·MedCommPeer-reviewed·Jul 30, 2026
- Fusion-derived phospho-neoepitopes define a prioritized candidate neoantigen repertoire in MASLD-HCC
Li Na Zhao, Jesper B. Andersen·bioRxiv·Aug 27, 2026
- ImmuniT Platform for Improved Neoantigen Prediction in Lung Cancer
Stephanie J. Hachey, Alexander G. Forsythe, … Christopher C.W. Hughes·VaccinesPeer-reviewed·Aug 29, 2025
- Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
S. Zhang, L. Yuan, … L. T. Kagohara·bioRxiv·Jan 10, 2023
- Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade
D. H. Shu, W. J. Ho, … M. Yarchoan·bioRxiv·Oct 16, 2023